Navigation Links
AEterna Zentaris and Sanofi-Aventis Sign a Development, Commercialization and Licensing Agreement for Cetrorelix in Benign Prostatic Hyperplasia
Date:3/6/2009

All amounts are in US dollars

QUEBEC CITY, March 6 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced the signing of a development, commercialization and licensing agreement with sanofi-aventis (EURONEXT: SAN; NYSE: SNY) for the development, registration and marketing of cetrorelix in benign prostatic hyperplasia (BPH) for the U.S. market. Cetrorelix, a luteinizing hormone-releasing hormone (LHRH) antagonist, is currently in a Phase 3 program in BPH, a non-cancerous enlargement of the prostate, affecting more than 20 million men in the U.S. alone.

Under the terms of the agreement, sanofi-aventis will make an initial $30 million upfront payment to AEterna Zentaris which will also be entitled to receive up to $135 million in additional payments upon achieving certain pre-established regulatory and commercial milestones. Furthermore, AEterna Zentaris will be entitled to receive escalating double-digit royalties on future net sales of cetrorelix for BPH in the United States. Sanofi-aventis will be responsible for the commercialization and booking of sales in the U.S.; however, AEterna Zentaris has retained certain rights to co-promote cetrorelix for BPH in the U.S. market. Finally, sanofi-aventis may perform future Phase 3b and Phase 4 clinical trials, while AEterna Zentaris will have free access to all data for other territories.

"We are delighted to have a partner such as sanofi-aventis who has a proven track record in urology. This partnership marks an important milestone in our quest to bring cetrorelix to market which could provide millions of men with a novel treatment for BPH. Furthermore, this compound could generate sign
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. AEterna Zentaris to Present at Upcoming RBC Capital Markets Healthcare Conference
2. AEterna Zentaris Closes Sale of Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners
3. AEterna Zentaris Reports Third Quarter 2008 Financial and Operating Results
4. AEterna Zentaris to Announce Third Quarter 2008 Financial and Operating Results on November 13, 2008
5. AEterna Zentaris Agrees to Sell Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners
6. AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Endometrial Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108
7. AEterna Zentaris to Present at Upcoming Oppenheimer 19th Annual Healthcare Conference
8. AEterna Zentaris Receives Notification from Nasdaq Relating to Minimum Bid Price
9. AEterna Zentaris Completes Patient Recruitment for Second Efficacy Trial of its Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia
10. AEterna Zentaris to Present at BioContact Quebec on October 2, 2008
11. AEterna Zentaris to Present at Upcoming CIBC World Markets 7th Annual Eastern Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... , Dec. 22, 2014   Synthetic ... developer of pathogen-specific therapies for serious infections ... the microbiome, today announced positive topline safety ... clinical trial of SYN-004, the Company,s investigational ... Clostridium difficile (C. difficile) infection, ...
(Date:12/22/2014)... 22, 2014  Alternative Energy & Environmental Solutions, ... signed a letter of intent to acquire BioTechPharma ... patented a nanotechnology-based development platform used to create ... rapid on-site collection and testing to identify infectious ... in an immediate, non-invasive and cost-effective manner. ...
(Date:12/22/2014)... , Dec. 22, 2014  ( www.competitivehealth.com ) ... an online medical bill review and advocacy service, has ... the FREE WellCard Savings discount health services marketplace. ... that was more than they expected to pay. As ... health care costs, WellCard Savings is pleased to offer ...
(Date:12/22/2014)... 22, 2014 ITRA Global, one of ... of commercial real estate, has further expanded its global ... Perth and Brisbane, Western Australia, reports Mylinda Vick, CCIM, ... ITRA Global / ACORPP (Australian Corporate Property and ... company providing property services to a wide range of ...
Breaking Biology Technology:Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5ALNE Announces Intention To Acquire BioTechPharma 2WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2
... Biologics, Inc.  (NYSE Amex: SYN ), a ... for serious illnesses, announced today that Jeff Riley, the ... Capital Partners 24th Annual Growth Stock Conference. The conference ... Carlton in Dana Point, CA. Mr. Riley will present ...
... and LONGNAN CITY, China, March 6, 2012   Apexigen, ... Duyiwei Biological Pharmaceutical Co., Ltd. (GDBP), which is ... that they entered into a collaboration to grant ... commercialize APX004 in China.   APX004 is a humanized ...
... ORLANDO, Fla., March 6, 2012 CSL Behring announced ... Esterase Inhibitor (Human) within six hours of the onset of ... symptom relief than later treatment, according to data presented at ... Annual Meeting. While HAE patients treated within six hours of ...
Cached Biology Technology:Synthetic Biologics to Present at ROTH Annual Growth Stock Conference 2Apexigen and Shanghai Duyiwei Biotechnology Co. Ltd Sign a License and Collaboration Agreement to Develop and Commercialize APX004 2Apexigen and Shanghai Duyiwei Biotechnology Co. Ltd Sign a License and Collaboration Agreement to Develop and Commercialize APX004 3CSL Behring Study Confirms Early Treatment with Berinert® Provides Faster Resolution of Acute Hereditary Angioedema Symptoms 2CSL Behring Study Confirms Early Treatment with Berinert® Provides Faster Resolution of Acute Hereditary Angioedema Symptoms 3CSL Behring Study Confirms Early Treatment with Berinert® Provides Faster Resolution of Acute Hereditary Angioedema Symptoms 4
(Date:12/15/2014)... Research and Markets ( http://www.researchandmarkets.com/research/87pph8/global_facial ... "Global Facial Recognition Market 2015-2019" report to ... Facial recognition is a technology ... system measures the overall facial feature of a ... the distance between eyes. Facial recognition is used ...
(Date:12/10/2014)... You,ve been here before: you desperately need to sign into ... key or the answer to your secret question. What,s your ... Today, Hoyos Labs , a digital infrastructure security ... an end to the frustration that comes with usernames, passwords ... a user,s smartphone to acquire his or her biometrics to ...
(Date:12/10/2014)... 9, 2014     ...   Jifflenow, a ... solutions for business-to-business (B2B) events, today announced a ... mobile near-field communication (NFC), Bluetooth low energy (BLE), ... http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow will integrate its ...
Breaking Biology News(10 mins):Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3
... -- Foiling exfiltration . . . Computer hackers ... developed by a team led by Justin Beaver of Oak ... attackers who breach a system,s defense have a distinct advantage ... window into potentially sensitive data and their true identity and ...
... Two new studies by researchers at the University of ... that eating rate plays in the amount of food ... faster than women, heavier people eat faster than slimmer ... grains, among other findings. Kathleen Melanson, URI associate ...
... of Mediterranean mountains could expand by up to 350% due to ... to cold and humid conditions, such as beech and Sylvester pines, ... possible in the 21st century according to a model created to ... Sistema Central and the Sistema Ibrico (Spain). A team led ...
Cached Biology News:Story tips from the US Department of Energy's Oak Ridge National Laboratory, November 2011 2Story tips from the US Department of Energy's Oak Ridge National Laboratory, November 2011 3Story tips from the US Department of Energy's Oak Ridge National Laboratory, November 2011 4Researcher provides further evidence that slow eating reduces food intake 2Holm oaks will gain ground in northern forests due to climate change 2
IKKbeta/IKK-2 Polyclonal Antibody 100 ug affinity purified rabbit polyclonal antibody. Reacts with human. Tested in Western blotting....
...
Request Info...
... The S.c. EasyComp Transformation Kit ... transformation-competent Saccharomyces cerevisiae cells. Advantages over ... spheroplast formation or LiCl methods include:- Cells ... than 30 minutes - Competent cell preparation ...
Biology Products: